Ratings for Johnson & Johnson JNJ were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 10 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 3 | 0 | 0 |
| 3M Ago | 0 | 7 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $191.2, a high estimate of $215.00, and a low estimate of $162.00. Experiencing a 0.02% decline, the current average is now lower than the previous average price target of $191.23.
Analyzing Analyst Ratings: A Detailed Breakdown
A comprehensive examination of how financial experts perceive Johnson & Johnson is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tim Anderson | B of A Securities | Announces | Neutral | $166.00 | - |
| Alexandria Hammond | Wolfe Research | Announces | Outperform | $190.00 | - |
| Vamil Divan | Guggenheim | Raises | Neutral | $162.00 | $156.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $185.00 | $180.00 |
| Larry Biegelsen | Wells Fargo | Raises | Equal-Weight | $166.00 | $163.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $181.00 | $178.00 |
| Terence Flynn | Morgan Stanley | Raises | Equal-Weight | $175.00 | $169.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $178.00 | $175.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $175.00 | $175.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson & Johnson. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Johnson & Johnson compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Johnson & Johnson's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Johnson & Johnson's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Johnson & Johnson analyst ratings.
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Johnson & Johnson: Delving into Financials
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Johnson & Johnson's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.25% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Johnson & Johnson's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 11.99%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Johnson & Johnson's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.8%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.5%, the company showcases effective utilization of assets.
Debt Management: Johnson & Johnson's debt-to-equity ratio is below the industry average at 0.51, reflecting a lower dependency on debt financing and a more conservative financial approach.
How Are Analyst Ratings Determined?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
